Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Assets Average (2016 - 2025)

Heron Therapeutics' Assets Average history spans 13 years, with the latest figure at $252.4 million for Q4 2025.

  • For Q4 2025, Assets Average rose 11.21% year-over-year to $252.4 million; the TTM value through Dec 2025 reached $252.4 million, up 11.21%, while the annual FY2025 figure was $244.5 million, 7.32% up from the prior year.
  • Assets Average reached $252.4 million in Q4 2025 per HRTX's latest filing, up from $240.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $378.3 million in Q3 2021 to a low of $211.1 million in Q2 2023.
  • Average Assets Average over 5 years is $260.0 million, with a median of $238.2 million recorded in 2023.
  • Peak YoY movement for Assets Average: plummeted 33.0% in 2021, then rose 11.21% in 2025.
  • A 5-year view of Assets Average shows it stood at $329.0 million in 2021, then fell by 20.54% to $261.5 million in 2022, then dropped by 13.62% to $225.9 million in 2023, then increased by 0.49% to $227.0 million in 2024, then rose by 11.21% to $252.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Assets Average are $252.4 million (Q4 2025), $240.5 million (Q3 2025), and $233.9 million (Q2 2025).